Agenus (AGEN) closed at $6.73 on November 13, 2026, down 2.0% from the previous close, on volume of 434,779 shares (30-day average 773,231).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 10, 2026 | Put Spread | 20-Nov-267 : 9 P | 826 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Fri, 6-Nov 9:00 AM ET)
Business Wire (Thu, 5-Nov 7:30 AM ET)
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
Business Wire (Mon, 2-Nov 6:05 PM ET)
Business Wire (Mon, 2-Nov 6:43 AM ET)
Business Wire (Sun, 25-Oct 7:00 AM ET)
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Business Wire (Thu, 22-Oct 4:30 PM ET)
Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference
Business Wire (Fri, 9-Oct 3:23 PM ET)
Business Wire (Thu, 8-Oct 7:30 AM ET)
Business Wire (Sat, 3-Oct 10:50 AM ET)
Business Wire (Fri, 2-Oct 9:00 AM ET)
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Agenus trades on the NASDAQ stock market under the symbol AGEN.
As of November 13, 2026, AGEN stock price declined to $6.73 with 434,779 million shares trading.
AGEN has a beta of 0.92, meaning it tends to be less sensitive to market movements. AGEN has a correlation of 0.02 to the broad based SPY ETF.
AGEN has a market cap of $304.51 million. This is considered a Small Cap stock.
Last quarter Agenus reported $31 million in Revenue and $.02 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.01.
In the last 3 years, AGEN traded as high as $19.69 and as low as $1.38.
The top ETF exchange traded funds that AGEN belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.
AGEN has outperformed the market in the last year with a return of +55.4%, while the SPY ETF gained +13.4%. However, in the most recent history, AGEN shares have underperformed the stock market with its stock returning -3.9% in the last 3 month period and -1.6% for the last 2 week period, while SPY has returned -2.8% and -0.2%, respectively.
AGEN support price is $6.50 and resistance is $7.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGEN shares will trade within this expected range on the day.
